What it is
Regulatory status: prescription-only in the United States, the European Union, UK, and Canada. Not OTC. Not a supplement. Not approved anywhere as a treatment for aging, healthspan, or “longevity.”
Mechanism evidence: human
At a glance
What it is, why people use it, the evidence, and what to know before trying it.
Why people use it
- **Glycemic control in type 2 diabetes** (approved).
- **Reduction of 3-point MACE and/or cardiovascular death in type 2 diabetes at high CV risk** (EMPA-REG, CANVAS, DECLARE-TIMI 58, VERTIS CV — results differ by drug and population).
- **HFrEF: fewer worsening-heart-failure events and, pooled, fewer deaths** (DAPA-HF, EMPEROR-Reduced).
- **HFmrEF / HFpEF: fewer worsening-heart-failure events** (EMPEROR-Preserved, DELIVER).
- **CKD: slower kidney-disease progression in T2D with albuminuria** (CREDENCE).
- **CKD: slower kidney-disease progression with or without diabetes** (DAPA-CKD, EMPA-KIDNEY).
- **Weight loss** (secondary / community claim; not an anti-obesity indication).
- **Blood-pressure reduction** (secondary pharmacodynamic claim).
- **Human lifespan extension / delayed aging in people without an approved indication** (longevity claim).
- **Mouse lifespan / healthspan** (preclinical; often presented as if it were human).
Evidence at a glance
SGLT2 inhibitors are **established prescription drugs** for type 2 diabetes glycemic control and, for specified agents, for heart failure across the ejection-fraction range and for CKD at risk of progression. The outcome evidence is among the strongest in cardiometabolic medicine: tens of thousands of randomized patients, hard events, and effect sizes that are large enough to change guidelines (MACE HR 0.86 in EMPA-REG and CANVAS; HFrEF primary HR 0.74–0.75; CKD primary HR 0.61–0.72; HFpEF primary HR 0.79–0.82). That evidence is **disease evidence**, generated in people with T2D, HF, or progressive CKD, in manufacturer-funded trials.